INM
InMed Pharmaceuticals Inc. NASDAQ Listed May 5, 2014$1.56
-1.89%
vs $1.59
Mkt Cap $1.5M
52w Low $0.61
37.0% of range
52w High $3.17
50d MA $1.24
200d MA $1.30
P/E (TTM)
0.0x
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.1x
ROE
-79.4%
P/FCF
-0.2x
RSI (14)
47.20
ATR (14)
$0.08
Beta
0.52
50d MA
$1.24
200d MA
$1.30
Avg Volume
289.2K
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
815 West Hastings Street · Vancouver, BC V6C 1B4 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | AMC | — | -0.51 | — | 0.99 | -2.2% | -10.1% | -1.5% | -3.1% | +1.1% | +0.1% | — |
| Nov 6, 2025 | AMC | — | -0.44 | — | 1.71 | -1.2% | -6.4% | +1.2% | +7.4% | -0.6% | +4.6% | — |
| Sep 23, 2025 | AMC | — | -3.80 | — | 2.14 | +1.9% | +1.9% | +0.0% | +0.5% | +3.7% | -3.5% | — |
| May 12, 2025 | AMC | — | -1.94 | — | 2.28 | +1.8% | +14.9% | +28.2% | -12.2% | +0.0% | -6.4% | — |
| Feb 12, 2025 | AMC | — | -3.64 | — | 3.20 | -1.6% | -3.1% | +1.9% | +0.3% | +5.0% | +1.8% | — |
| Nov 14, 2024 | AMC | — | -54.20 | — | 5.08 | +0.0% | -15.7% | -0.9% | +2.6% | -2.8% | +9.9% | — |
| Sep 27, 2024 | AMC | — | -3.80 | — | 4.64 | +3.4% | +2.2% | -6.3% | -0.7% | -1.4% | -7.1% | — |
| May 14, 2024 | AMC | — | -3.60 | — | 5.34 | +0.4% | +2.6% | +4.0% | +3.5% | +10.5% | +0.9% | — |
| Feb 13, 2024 | AMC | — | -3.80 | — | 7.12 | +9.8% | -2.0% | -0.6% | -1.2% | +9.6% | +7.3% | — |
| Nov 14, 2023 | AMC | — | -15.20 | — | 7.72 | -5.3% | +5.2% | -1.8% | +13.4% | -10.4% | -6.2% | — |
| Sep 29, 2023 | AMC | -85.00 | -12.92 | +84.8% | 14.00 | +2.8% | -3.6% | +5.6% | -5.0% | +0.1% | +5.0% | — |
| May 15, 2023 | AMC | -90.00 | -12.00 | +86.7% | 23.20 | -1.7% | -0.9% | +0.0% | +20.9% | -1.4% | +2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $735.00 | $730.00 | -0.7% | +0.7% | +1.4% | -6.0% | -4.3% | -2.2% |
| Feb 16 | Roth Capital | Maintains | Buy → Buy | — | $2665.00 | $2740.00 | +2.8% | -3.0% | -6.8% | -8.1% | -1.4% | +9.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Vivo Opportunity, LLC10% | — | Buy | 147 | $1.55 | $228 | 73,135 | — | — |
| Jul 2, 2026 | Vivo Opportunity, LLC10% | — | Buy | 1,460 | $1.55 | $2K | 724,395 | — | — |
| Jul 1, 2026 | Vivo Opportunity, LLC10% | — | Buy | 398 | $1.55 | $617 | 72,988 | — | — |
| Jul 1, 2026 | Vivo Opportunity, LLC10% | — | Buy | 3,946 | $1.55 | $6K | 722,935 | — | — |
| Jun 30, 2026 | Vivo Opportunity, LLC10% | — | Buy | 55 | $1.54 | $85 | 72,590 | — | — |
| Jun 30, 2026 | Vivo Opportunity, LLC10% | — | Buy | 545 | $1.54 | $839 | 718,989 | — | — |
| Jun 8, 2026 | Vivo Opportunity, LLC10% | — | Buy | 2,982 | $1.52 | $5K | 72,535 | +4.64% | +0.68% |
| Jun 8, 2026 | Vivo Opportunity, LLC10% | — | Buy | 29,518 | $1.52 | $45K | 718,444 | +4.64% | +0.68% |
| Jun 5, 2026 | Vivo Opportunity, LLC10% | — | Buy | 5,045 | $1.57 | $8K | 69,553 | +4.64% | +0.68% |
| Jun 5, 2026 | Vivo Opportunity, LLC10% | — | Buy | 49,966 | $1.57 | $78K | 688,926 | +4.64% | +0.68% |
| Jun 4, 2026 | Vivo Opportunity, LLC10% | — | Buy | 618 | $1.57 | $970 | 64,508 | +4.64% | +0.68% |
| Jun 4, 2026 | Vivo Opportunity, LLC10% | — | Buy | 6,125 | $1.57 | $10K | 638,960 | +4.64% | +0.68% |
| Jun 3, 2026 | Vivo Opportunity, LLC10% | — | Buy | 714 | $1.55 | $1K | 63,890 | +4.64% | +0.68% |
| Jun 3, 2026 | Vivo Opportunity, LLC10% | — | Buy | 7,069 | $1.55 | $11K | 632,835 | +4.64% | +0.68% |
| Jun 2, 2026 | Vivo Opportunity, LLC10% | — | Buy | 2,095 | $1.52 | $3K | 63,176 | +4.64% | +0.68% |
| Jun 2, 2026 | Vivo Opportunity, LLC10% | — | Buy | 20,753 | $1.52 | $32K | 625,766 | +4.64% | +0.68% |
| Jun 1, 2026 | Vivo Opportunity, LLC10% | — | Buy | 1,498 | $1.55 | $2K | 61,081 | +4.64% | +0.68% |
| Jun 1, 2026 | Vivo Opportunity, LLC10% | — | Buy | 14,838 | $1.55 | $23K | 605,013 | +4.64% | +0.68% |
| May 29, 2026 | Vivo Opportunity, LLC10% | — | Buy | 1,632 | $1.57 | $3K | 59,583 | +4.64% | +0.68% |
| May 29, 2026 | Vivo Opportunity, LLC10% | — | Buy | 16,164 | $1.57 | $25K | 590,175 | +4.64% | +0.68% |
| May 21, 2026 | Vivo Opportunity, LLC10% | — | Buy | 3,118 | $1.69 | $5K | 57,951 | +4.64% | +0.68% |
| May 21, 2026 | Vivo Opportunity, LLC10% | — | Buy | 30,882 | $1.69 | $52K | 574,011 | +4.64% | +0.68% |
| May 20, 2026 | Vivo Opportunity, LLC10% | — | Buy | 5,154 | $1.56 | $8K | 54,833 | +4.64% | +0.68% |
| May 20, 2026 | Vivo Opportunity, LLC10% | — | Buy | 51,056 | $1.56 | $80K | 543,129 | +4.64% | +0.68% |
S-4
!!! Very High
InMed Pharmaceuticals Inc. -- Merger Registration
Jul 2
8-K · 8.01
!! High
InMed Pharmaceuticals Inc. -- 8-K 8.01: Material Event / Announcement
Jun 10
8-K · 8.01
!! High
InMed Pharmaceuticals Inc. -- 8-K 8.01: Material Event / Announcement
May 19
8-K
InMed Pharmaceuticals Inc. -- 8-K Filing
May 19
8-K · 7.01
! Medium
InMed Pharmaceuticals Inc. -- 8-K 7.01: Regulation FD Disclosure
InMed Pharmaceuticals reported Q3 fiscal 2026 results, providing investors with updated financial performance metrics and operational developments through March 31, 2026.
May 7
8-K · 1.01
!! High
InMed Pharmaceuticals Inc. Common Shares -- 8-K 1.01: Material Agreement
InMed Pharmaceuticals amended its preferred investment agreement with Sab, modifying terms of a prior investment arrangement that could affect the company's capital structure and ownership dynamics.
Apr 27
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This 8-K filing appears incomplete or misfiled, containing only legal firm contact information without substantive material event disclosures, making it impossible to assess impact on INM stock without additional context.
Apr 3
8-K
Unknown — 8-K Filing
INM faces delisting risk from Nasdaq unless it restores minimum market capitalization, requiring a potential reverse stock split that could further pressure shareholders already dealing with significant stock decline.
Mar 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
InMed's preclinical Alzheimer's data strengthens INM-901's therapeutic potential and could expand market opportunity, justifying investor interest if development progresses to clinical trials.
Mar 23
8-K · 7.01
! Medium
InMed Pharmaceuticals Inc. Common Shares -- 8-K 7.01: Regulation FD Disclosure
InMed Pharmaceuticals disclosed its 2026 pharmaceutical development pipeline strategy, providing investors visibility into the company's planned clinical and research milestones for the year ahead.
Mar 9
8-K · 7.01
! Medium
InMed Pharmaceuticals Inc. Common Shares -- 8-K 7.01: Regulation FD Disclosure
InMed Pharmaceuticals is winding down commercial operations, signaling a strategic retreat that will likely result in significant shareholder value destruction and potential delisting risk.
Mar 6
8-K · 7.01
! Medium
InMed Pharmaceuticals Inc. Common Shares -- 8-K 7.01: Regulation FD Disclosure
InMed Pharmaceuticals reported Q2 FY2026 financial results, providing investors with updated performance metrics for the period ending December 31, 2025.
Feb 12
Valuation
Market Cap
$1.5M
Enterprise Value
-$13.6M
P/E (TTM)
0.00x
Forward P/E
—
PEG Ratio
0.01x
P/B
0.08x
P/S
0.38x
P/FCF
-0.20x
EV/EBITDA
—
Shares Out
976K
Financials (TTM)
Revenue
$4.0M
Net Income
-$9.9M
EBITDA
-$9.2M
Free Cash Flow
-$7.8M
Op Cash Flow
-$7.8M
EPS Basic
$-11.44
EPS Diluted
$-1142.54
EPS Forward
—
Gross Margin
30.4%
Op Margin
-246.8%
Net Margin
-246.4%
Balance Sheet
Total Assets
$21.2M
Total Liab.
$2.9M
Total Equity
$18.3M
Cash
$15.1M
LT Debt
$0
Book Value/Sh
$18.75
Debt/Equity
0.06x
Current Ratio
6.99
Quick Ratio
6.47
Returns & Growth
ROE
-79.4%
ROA
-68.0%
ROIC
-41.0%
Rev Growth YoY
+7.5%
EPS Growth YoY
+58.5%
Price Returns
2W
+4.7%
1M
-1.9%
3M
+124.6%
6M
+39.3%
12M
-46.4%
Technicals
52W High
$3.17
52W Low
$0.61
50d MA
$1.24
200d MA
$1.30
RSI (14)
47.20
ATR (14)
$0.08
Beta
0.52
Avg Volume
289K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 3:40pm
· Source: financialmodelingprep.com